HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
The Week

'Not simply saving cost': Inside Astellas CEO's 5-year strategy to counter Xtandi's patent cliff

Staring down a $6 billion patent cliff for its prostate cancer drug Xtandi, Astellas aims to counter the inevitable revenue decline with a 200 billion yen ($1.3 billion) cost-savings program anchored in its new five-year strategic plan. But to CEO Naoki Okamura, "it's not simply saving the cost or r

By FiercePharma · Jun 12, 2026 · via FiercePharma
'Not simply saving cost': Inside Astellas CEO's 5-year strategy to counter Xtandi's patent cliff

Image: FiercePharma

This is an aggregated industry headline. Read the full story at FiercePharma →

Tags
theweekformat:headlineheadlineFiercePharma
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
Novartis' phase 1/2 win tees up regulatory talks about dystrophy drug from $12B Avidity takeover
The WeekFierceBiotech ↗
Novartis' phase 1/2 win tees up regulatory talks about dystrophy drug from $12B Avidity takeover
Novartis has reported a phase 1/2 win for one of the jewels of its $12 billion Avidity Biosciences buyout, set…
Jun 12, 2026
J&J’s Imaavy Secures Trial Win, Eyes First Approval in Warm Autoimmune Hemolytic Anemia
The WeekBriefing
J&J’s Imaavy Secures Trial Win, Eyes First Approval in Warm Autoimmune Hemolytic Anemia
Johnson & Johnson reported pivotal trial success for Imaavy in warm autoimmune hemolytic anemia, a rare diseas…
Jun 12, 2026
STAT+: At hospital finance conference, a call to end the friction that's keeping costs high
The WeekSTAT News ↗
STAT+: At hospital finance conference, a call to end the friction that's keeping costs high
Hospital execs agree that affordability is a major issue. What to do about it is less clear.…
Jun 12, 2026